Cytarabine 100 mg/ml Solution for Injection or Infusion

DRUG3 trials

Sponsors

Prinses Maxima Centrum voor Kinderoncologie B.V., Janssen - Cilag International, AbbVie Deutschland GmbH & Co. KG

Conditions

Acute Myeloid Leukemia

Phase 1

A Phase 1b Study of Bleximenib in Combination with AML Directed Therapies for Participants with Acute Myeloid Leukemia Harboring KMT2A or NPM1 Alterations

Active, not recruitingCTIS2023-506582-58-00

Janssen - Cilag InternationalAcute Myeloid Leukemia

Start: 2022-07-21Target: 86Updated: 2025-10-03

Phase 3

CHIP-AML22 Master protocol: An open label complex clinical trial in newly diagnosed pediatric de novo AML patients – a study by the NOPHO-DB-SHIP consortium Master Protocol

RecruitingCTIS2023-504999-25-00

Prinses Maxima Centrum voor Kinderoncologie B.V.Acute Myeloid Leukemia

Start: 2023-07-14Target: 675Updated: 2025-08-14

A Randomized, Double-Blind, Placebo Controlled Study of Venetoclax Co-Administered with Low Dose Cytarabine Versus Low Dose Cytarabine in Treatment Naïve Patients with Acute Myeloid Leukemia Who Are Ineligible for Intensive Chemotherapy

CompletedCTIS2024-513630-37-00

AbbVie Deutschland GmbH & Co. KGAcute Myeloid Leukemia

Start: 2017-10-24End: 2025-06-23Target: 1Updated: 2024-07-01